Drug

Foresee Pharmaceuticals Announces China NMPA Approval of CAMCEVI® 42 mg for Advanced Prostate Cancer – GenSci to Commercialize the 6‑Month Leuprolide Depot
Foreseen BiotechnologyGeneScience Pharmaceutical

Foresee Pharmaceuticals Announces China NMPA Approval of CAMCEVI® 42 mg for Advanced Prostate Cancer – GenSci to Commercialize the 6‑Month Leuprolide Depot

Foresee Pharmaceuticals (TPEx: 6576) ("Foresee") announced that it was notified by its licensing partner, Changchun GeneScience Pharmaceutical Co., Ltd. ("GenSci"), that China's National Medical Products Administration (NMPA) has approved the…

InnoCare's TL1A/IL‑23p19 Bispecific Antibody ICP‑B161 Cleared for Clinical Trials – Fifth Innovative Drug IND of 2026 Targets Inflammatory Bowel Disease

InnoCare’s TL1A/IL‑23p19 Bispecific Antibody ICP‑B161 Cleared for Clinical Trials – Fifth Innovative Drug IND of 2026 Targets Inflammatory Bowel Disease

Kangtai Biological Products Initiates Phase I Trial of Adult, Adolescent and Pediatric Acellular Pertussis‑Diphtheria‑Tetanus (Component) Combination Vaccine – First Subject Enrolled

Kangtai Biological Products Initiates Phase I Trial of Adult, Adolescent and Pediatric Acellular Pertussis‑Diphtheria‑Tetanus (Component) Combination Vaccine – First Subject Enrolled

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
Fosun PharmaceuticalHKG: 2196

Fosun Pharma’s Tenapanor (Vteglea) Issues First China Prescription – NHE3 Inhibitor Targets Hyperphosphatemia in Dialysis Patients

Clinical trial resultsMulti-specific antibodies

Pfizer’s Tilrekimig Hits Phase 2 Primary Endpoint – IL-4/IL-13/TSLP Trispecific Shows 52% EASI-75 Response in Atopic Dermatitis

FDA Accepts ENHERTU sBLA with Priority Review – HER2 ADC Seeks Early Breast Cancer Approval with 53% Recurrence Risk Reduction
ADC / XDCAstraZeneca

FDA Accepts ENHERTU sBLA with Priority Review – HER2 ADC Seeks Early Breast Cancer Approval with 53% Recurrence Risk Reduction

J&J Files TECVAYLI Line Extension with EMA – BCMA Bispecific Seeks Earlier Use in Second-Line Multiple Myeloma
J&JJohnson & Johnson

J&J Files TECVAYLI Line Extension with EMA – BCMA Bispecific Seeks Earlier Use in Second-Line Multiple Myeloma

Show More